3M Company

NYSE:MMM Rapport sur les actions

Capitalisation boursière : US$77.9b

3M Dividendes et rachats

Dividende contrôle des critères 3/6

3M est une société versant des dividendes avec un rendement actuel de 2.08% qui est bien couvert par les bénéfices. La prochaine date de paiement est le 12th June, 2026 avec une date ex-dividende de 22nd May, 2026.

Informations clés

2.1%

Rendement du dividende

3.9%

Rendement des rachats

Rendement total pour l'actionnaire6.0%
Rendement futur des dividendes2.4%
Croissance des dividendes-0.3%
Prochaine date de paiement du dividende12 Jun 26
Date ex-dividende22 May 26
Dividende par actionn/a
Ratio de distribution57%

Mises à jour récentes sur les dividendes et les rachats

Recent updates

Seeking Alpha May 15

3M: Iran Conflict And Inflationary Pressure Could Derail The Recovery

Summary 3M Company remains a hold as macro risks and litigation liabilities constrain its upside despite an otherwise solid business. MMM reported a solid Q1 2026 with 3.9% YoY adjusted sales growth, robust cash flow, and continued portfolio optimization, including a strategic fire and safety JV. Rising material costs, especially from oil-based inputs, and heightened macro uncertainty from Middle East conflicts threaten margins and valuation. Current valuation doesn't seem to imply a good enough margin of safety, while macro pressure and uncertainty justify a cautious stance. Read the full article on Seeking Alpha
Mise à jour du récit May 03

MMM: Future Margin Execution And Buybacks Will Support Turnaround Prospects

Analysts have adjusted the 3M price target slightly lower to reflect a new fair value near $175, as recent target cuts from several firms and one smaller increase from Wells Fargo suggest a more cautious view on profit margins, while revenue growth assumptions and future P/E expectations remain steady to slightly higher. Analyst Commentary Recent Street research reflects a more mixed stance on 3M, with several firms trimming price targets and one lifting its target, all clustering around a fair value in the mid US$170s.
Mise à jour du récit Apr 18

MMM: Execution On Margin Efficiency And Buybacks Will Support Future Re Rating

Analysts have trimmed their 3M fair value estimate by about $2 to $223.59, reflecting slightly lower profit margin assumptions that are only partly balanced by a modestly higher revenue growth outlook and a marginally richer future P/E multiple. Analyst Commentary Recent Street research on 3M reflects a mix of cautious revisions and selective optimism, with several firms adjusting price targets both higher and lower in response to updated assumptions.
Nouveau récit Apr 11

3M Company (MMM): The "Industrial Rebirth" and the 2026 Operational Pivot

3M Company (MMM) closed the April 10, 2026, session at $150.32 USD on the NYSE, ending the week with a slight 0.12% daily decline. After years of being defined by sprawling litigation and a complex conglomerate structure, the central narrative for 2026 is "The Great Operational Reset" : Following the successful 2024 spinoff of its healthcare arm, Solventum (SOLV) , and the resolution of major PFAS and earplug legal tranches, 3M has emerged as a streamlined materials science specialist.
Mise à jour du récit Apr 04

MMM: Operational Discipline And Legal Resolution Will Support Future Re Rating

Analysts have reduced the updated price target on 3M by about $1 to $225.94. This reflects a combination of recent target cuts and increases across firms, along with slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E.
Mise à jour du récit Mar 21

MMM: Operational Progress And Legal Overhang Resolution Will Support Future Re Rating

The analyst price target for 3M has been adjusted by a few dollars, reflecting mixed but generally constructive updates from recent research. Some firms raised their targets by $2 to $5, while others trimmed theirs by $6 to $8, based on refreshed views of growth, profitability, and valuation assumptions.
Mise à jour du récit Mar 06

MMM: Digital And Legal Progress Will Support Future Re Rating

The analyst price target for 3M has edged higher by about $1.50, as analysts weighed mixed target moves from major firms alongside slightly updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent Street research on 3M has been mixed, with some firms trimming their price targets while others raised theirs.
Mise à jour du récit Feb 20

MMM: Digital Execution And Slightly Higher Fair Value Will Support Re Rating

The analyst price target for 3M has shifted slightly higher, with our fair value estimate moving from $223.00 to about $225.67 as analysts factor in updated growth and margin assumptions, along with mixed target revisions across major firms. Analyst Commentary Recent Street research on 3M shows a split view, with several bullish analysts lifting price targets and others trimming expectations or downgrading the stock.
Mise à jour du récit Feb 05

MMM: Turnaround Prospects Will Be Tested By PFAS Litigation And Mixed Street Expectations

The analyst price target on 3M has been revised slightly higher to about $177 from $174, as analysts adjust their models for small changes in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions following a mix of recent target increases and cuts across major firms. Analyst Commentary Recent Street research on 3M has been mixed, with several firms adjusting their price targets in both directions and one major downgrade.
Mise à jour du récit Jan 22

MMM: New Digital Tools And Higher P E Multiple Will Support Re Rating

Analysts have nudged their valuation view on 3M higher, with the updated fair value estimate moving from $212 to $223 as they reassess the stock's longer term earnings power and apply a slightly richer future P/E multiple, despite mixed recent price target changes across the Street. Analyst Commentary Recent Street research on 3M has been mixed, with some firms trimming targets or ratings and others lifting their valuation marks.
Mise à jour du récit Jan 07

MMM: Reset Expectations And New Products Will Support Higher Margins

Analysts have raised their fair value estimate for 3M to $212 from $187, citing expectations for higher profit margins, a slightly lower discount rate, and supportive Street research that highlights Q3 execution, new product traction, and reset expectations across multiple firms. Analyst Commentary Recent Street research around 3M clusters around a more constructive setup following Q3, with several bullish analysts revisiting their models on the back of reset expectations, new product traction, and updated legal and macro assumptions.
Mise à jour du récit Dec 24

MMM: PFAS Litigation Will Ultimately Cap Upside Despite Turnaround Progress

Analysts have raised their price target on 3M, lifting fair value by about $12 per share to roughly $126 as they grow more confident in the company’s improving organic growth, margin expansion, and turnaround initiatives, despite ongoing PFAS litigation risks. Analyst Commentary Recent Street research reflects a more balanced, but still risk aware, view on 3M as estimates reset and execution on the turnaround improves.
Mise à jour du récit Dec 10

MMM: Turnaround Progress Will Face Ongoing PFAS Litigation And Portfolio Reshaping Risks

Our fair value estimate for 3M has been trimmed slightly to $174.25 from $174.94 as analysts balance higher price targets and improving expectations for new product driven growth and management's turnaround progress against persistent PFAS litigation risk. Analyst Commentary Street research remains divided on 3M, with recent notes highlighting improving execution and product driven growth, offset by continued concern around PFAS liabilities and mixed end market demand.
Mise à jour du récit Nov 26

MMM: Shares Will Balance Turnaround Progress With Litigation and Asset Sale Uncertainty

Analysts have marginally raised their fair value estimate for 3M to $174.94, citing improved organic growth, ongoing new product introductions, and increased profit margin expectations following recent quarterly results. Analyst Commentary Recent analyst research has revealed a shifting perspective on 3M, as several experts adjust their outlooks based on the company’s latest earnings performance and ongoing strategic initiatives.
Mise à jour du récit Nov 06

MMM: Shares Will Balance Turnaround Progress With Ongoing Litigation and Portfolio Changes

Analysts have raised their fair value estimate for 3M to $174.31 from $167.81. This change reflects improved organic growth prospects and progress on turnaround initiatives highlighted in recent research updates.
Mise à jour du récit Oct 22

Analysts Divided on 3M as Fair Value Rises Amid New Initiatives and Persistent Risks

3M's fair value estimate has increased by $5.00 to $167.81 as analysts cite modest operating outperformance and positive momentum from new product initiatives, despite some lingering concerns. Analyst Commentary Recent updates from Street research highlight diverging analyst sentiment regarding 3M's valuation trajectory and execution on strategic initiatives.
Mise à jour du récit Oct 08

New Product Launches And Efficiency Gains Will Boost Future Value

Narrative Update: 3M Analyst Price Target Revision Analysts have increased their price target for 3M to $162.81 from $161.63, citing improved full-year guidance prospects and renewed interest as a short-term buy idea. Analyst Commentary Recent commentary from Street research highlights both optimistic and cautious stances regarding 3M’s near-term prospects.
Seeking Alpha Mar 11

3M: Multiple Expansion Amidst Turnaround Success

Summary 3M has shown signs of a turnaround with a doubling stock price since October 2023, but operational top line growth remains modest, justifying a "hold" rating. The company expects modest organic revenue growth of 2-3% in 2025, driven by innovations and new product launches, but analysts are less optimistic. Current valuation is high with a forward P/E ratio above the five-year median, limiting upside potential amid risks like trade disputes and economic slowdowns. Read the full article on Seeking Alpha
Seeking Alpha Feb 07

3M: More Upside Ahead - But Wait For A Moderate Retracement

Summary MMM's reversal is already here, thanks to the SOLV divestiture bringing forth a more focused portfolio and healthier balance sheet. This is on top of the resolution of its legal headwinds, as management also pursues insurance recovery and $340M already completed. The management has driven new growth opportunities through its legacy businesses and new product launches as well, despite certain market softness. These reasons are likely why the market has upgraded MMM's valuations and the investors have defended the stock's uptrend support line thus far. With double digit capital appreciation prospects, we are reiterating our Buy rating here with one caveat. We shall further discuss. Read the full article on Seeking Alpha
Seeking Alpha Jan 23

3M Is Structurally Shifting For Durable Growth

Summary 3M's focus on innovation and operational improvements under CEO Bill Brown may lead to significant top-line growth and margin expansion. Management is aiming to enhance supply chain efficiencies and increasing production launches while improving the firm's on-time, in-full deliveries. 3M has a substantial amount of inventory that may be worked down in the coming quarters, potentially acting as a tailwind for free cash flow generation in the coming years. Read the full article on Seeking Alpha
Seeking Alpha Jan 06

Downgrading 3M Due To Persistent Litigation Risks And Stagnant Sales Growth

Summary I am downgrading 3M from hold to sell due to slow revenue growth, ongoing litigation risks, and inflated stock valuation despite recent gains. Revenue growth is expected to underpace inflation, driven by product line adjustments, declining European demand, and the healthcare spin-off. Despite settling some litigations, 3M faces significant pending lawsuits, posing substantial financial risks. Shares appear expensive when accounting for slow growth and litigation risks, with a fair value estimate of $86 per share, 34% below current trading. Read the full article on Seeking Alpha
Seeking Alpha Dec 30

One Of JPMorgan's Value Picks For 2025, 3M Could Have A Bright Year Ahead

Summary JPMorgan highlights 3M Company as a key investment idea for 2025, despite ongoing legal challenges and growth issues, leading to my Hold rating. 3M's diverse operations span Safety & Industrial, Transportation & Electronics, Consumer, and Healthcare, with a strong focus on innovation and high-margin products. The company reported 1% organic growth and an 18% rise in adjusted EPS for Q3 2024, showcasing operational efficiency and cost management. With a healthy 23% margin and $1.5 billion free cash flow, MMM balances rewarding shareholders with investing in growth initiatives. Read the full article on Seeking Alpha
Seeking Alpha Nov 25

3M: Seems A Bit Too Expensive Considering The Slow Growth

Summary Earlier this year, CEO William Brown said 3M's products are aging. Now and in the near future, it seems like the company is focussing on new products and research. It seems like the uncertainty-creating lawsuits are now largely settled, but the costs will weigh on the company for several years to come. Nevertheless, 3M has a strong financial position and rewards its shareholders with dividends and buybacks, but I'm waiting because I believe it is slightly too expensive. Read the full article on Seeking Alpha
Seeking Alpha Oct 24

3M: Multiple Expansion But Problems Linger

Summary 3M's Q3 earnings beat expectations with $1.98/share, driven by margin expansion from restructuring, despite lackluster 1.5% organic revenue growth. The company repurchased $700 million in stock, raising concerns about prioritizing buybacks over addressing future PFAS liabilities and debt reduction. 3M faces significant PFAS-related lawsuits, posing potential billions in liabilities, making stock buybacks questionable given the financial risks. Despite a 30% stock appreciation, driven by multiple expansion, revenue growth remains below inflation, and future liabilities pose significant downside risks. Read the full article on Seeking Alpha
Seeking Alpha Oct 01

3M's Transformation Uncertain: A Wait-And-See Approach

Summary 3M is undergoing a challenging transformation with stagnant revenue, rising debt, and significant legal risks from PFAS litigation, leading to a 32% stock price decline since 2021. Despite a strong global product portfolio and solid cash flow, current free cash flow is insufficient to cover dividends and share buybacks, raising concerns. New CEO William Brown brings valuable experience but skepticism remains about his ability to drive a radical transformation, given past performance and substantial PFAS liabilities. I estimate 3M's value at $125 per share, slightly lower than its current price, and recommend holding due to unclear recovery path. Read the full article on Seeking Alpha
Seeking Alpha Aug 30

3M: A Bright Future, But Shares Hit Fair Value Amid Strong Momentum (Rating Downgrade)

Summary 3M's Q2 earnings report was exceptionally strong, leading to a 23% stock surge and a 46% YTD performance, the best in the DJIA. Despite robust technical momentum and a rising trend, 3M's stock is close to fair value, warranting a hold rating for now. Key risks include potential macroeconomic slowdowns, a strong US dollar, and an untested new CEO, but future EPS growth looks promising. With a decent 2.11% dividend yield and potential for payout boosts, 3M's long-term growth trajectory appears stable post-Solventum spinoff. I outline key price levels to monitor on chart, as momentum remains very impressive. Read the full article on Seeking Alpha
User avatar
Nouveau récit Aug 20

Restructuring And Critical Shifts Poised To Transform Operational Efficiencies And Net Margins

Restructuring and focusing on high-growth areas like auto electrification and climate tech are set to drive margin expansions and top-line growth.
Seeking Alpha Aug 01

3M's New CEO Spills The Beans

Summary 3M's core was tired before the new CEO, Bill Brown, took over. In the recent earnings call, he spilled the beans on this fact. He is displaying leadership and didn't mention AI one time, yet turning around the culture in a company like 3M is no small task. Investors who purchased 3M early this year and sold the Solventum shares have experienced gains exceeding 60%. My target price is $86. The market may move it to more like $110. Read the full article on Seeking Alpha

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Les paiements de dividendes de MMM ont été volatils au cours des 10 dernières années.

Dividende croissant: Les paiements de dividendes de MMM ont diminué au cours des 10 dernières années.


Rendement des dividendes par rapport au marché

3M Rendement des dividendes par rapport au marché
Comment le rendement du dividende de MMM se compare-t-il à celui du marché ?
SegmentRendement du dividende
Entreprise (MMM)2.1%
25% du marché (US)1.4%
25% du marché (US)4.3%
Moyenne du secteur (Industrials)2.6%
Analyste prévisionnel (MMM) (jusqu'à 3 ans)2.4%

Dividende notable: Le dividende de MMM ( 2.08% ) est supérieur à celui des 25 % des payeurs de dividendes les plus faibles du marché US ( 1.42% ).

Dividende élevé: Le dividende de MMM ( 2.08% ) est faible par rapport aux 25 % des premiers payeurs de dividendes du marché US ( 4.27% ).


Bénéfice distribué aux actionnaires

Couverture des revenus: Grâce à son ratio de distribution raisonnable (56.9%), les dividendes versés par MMM sont couverts par les bénéfices.


Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Avec son taux de distribution en espèces actuel ( 79% ), les paiements de dividendes de MMM sont couverts par les flux de trésorerie.


Découvrir des entreprises qui versent des dividendes élevés

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/20 11:11
Cours de l'action en fin de journée2026/05/20 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

3M Company est couverte par 30 analystes. 13 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
John EadeArgus Research Company
Julian MitchellBarclays
Robert CornellBarclays